Skip to main
SGRY

Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners (SGRY) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Surgery Partners is well positioned for long-term growth and earnings potential, supported by strong leadership, a diverse and talented workforce, and a strategic focus on high-acuity procedures. The recent divestiture of its Idaho Falls market removes a key overhang and allows the company to focus on its core business of ambulatory surgical centers. The company's targeted growth strategy, impressive track record with physician recruitment, and disciplined approach to M&A present attractive opportunities for future growth. While there may be risks related to reimbursement rates and labor costs, the company's efficient operating model and strong management should help mitigate these factors.

Bears say

Surgery Partners is struggling to maintain sustainability due to concerns surrounding both workforce diversity and environmental impact. Despite taking steps to address COVID-19 safety measures, the pandemic has also significantly impacted the company's financials, with lower volumes and higher debt. Their valuation may also be negatively impacted by their mix of mature and emerging healthcare providers in their portfolio, as well as potential market corrections and recessions.

Surgery Partners (SGRY) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surgery Partners (SGRY) Forecast

Analysts have given Surgery Partners (SGRY) a Buy based on their latest research and market trends.

According to 8 analysts, Surgery Partners (SGRY) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surgery Partners (SGRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.